Achillion Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Description: Achillion Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct's pharmaceuticals report, “Achillion Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Achillion Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Achillion Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Achillion Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Achillion Pharmaceuticals, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Achillion Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Achillion Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Achillion Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Achillion Pharmaceuticals, Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Achillion Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Contents:

List of Tables
List of Figures
Achillion Pharmaceuticals, Inc. Snapshot
Achillion Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Achillion Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Achillion Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Achillion Pharmaceuticals, Inc. – Pipeline Products Glance
Achillion Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Achillion Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Achillion Pharmaceuticals, Inc. – Drug Profiles
ACH-1625
Product Description
Mechanism of Action
R&D Progress
Elvucitabine
Product Description
Mechanism of Action
R&D Progress
ACH-1095
Product Description
Mechanism of Action
R&D Progress
ACH-2684
Product Description
Mechanism of Action
R&D Progress
ACH-2928
Product Description
Mechanism of Action
R&D Progress
ACH-702
Product Description
Mechanism of Action
R&D Progress
HCV Inhibitor Program
Product Description
Mechanism of Action
R&D Progress
Achillion Pharmaceuticals, Inc. – Pipeline Analysis
Achillion Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Achillion Pharmaceuticals, Inc. Pipeline Products By Target
Achillion Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Achillion Pharmaceuticals, Inc. - Dormant Projects
Achillion Pharmaceuticals, Inc. – Company Statement
Achillion Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Sep 30, 2010: Achillion Doses First Patient In Phase II Trial Of ACH-1625 For Treatment Of Hepatitis C
Jul 22, 2010: Achillion Announces Nomination Of NS5A Inhibitor As Lead Clinical Candidate For Treatment Of HCV
May 11, 2010: Achillion Announces Positive Once-Daily Dosing Results With ACH-1625 To Treat Hepatitis C
Apr 15, 2010: Achillion Presents Data From Phase I Clinical Trial Of ACH-1625 In Hepatitis C
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
Mar 25, 2010: Achillion Receives Patent For NS4A
May 25, 2010: Achillion Receives Patent For NS4A
Financial Deals Landscape
Achillion Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Achillion Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Achillion Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Achillion Pharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
Achillion Pharmaceuticals Completes Public Offering Of $25 Million
Achillion Pharmaceuticals Announces Private Placement Of $15 Million
Achillion Pharmaceuticals Completes Initial Public Offering Of $59.5 Million
Licensing Agreements
Achillion Pharmaceuticals Enters Into Licensing Agreement With GCA Therapeutics
Achillion Pharmaceuticals Enters Into Licensing Agreement With FOB Synthesis
Achillion Pharmaceuticals Enters Into Licensing Agreement with Gilead Sciences

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Achillion Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Web Address: http://www.researchandmarkets.com/reports/1446121/
Office Code: SCD2Y3Q1

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World